Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial

Eric Van Cutsem, Sanne de Haas, Yoon‐Koo Kang, Atsushi Ohtsu, Niall C. Tebbutt, Jianming Xu, Wei Peng Yong, Bernd Langer, Paul Delmar, Stefan Scherer, Manish A. ShahJournal of Clinical Oncology 2012 · DOI

Abstract

Plasma VEGF-A and tumor neuropilin-1 are strong biomarker candidates for predicting clinical outcome in patients with advanced gastric cancer treated with bevacizumab.
BibTeX
@article{cutsem2012bevacizumab,
  author = {Eric Van Cutsem and Sanne de Haas and Yoon‐Koo Kang and Atsushi Ohtsu and Niall C. Tebbutt and Jianming Xu and Wei Peng Yong and Bernd Langer and Paul Delmar and Stefan Scherer and Manish A. Shah},
  title = {{Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial}},
  journal = {Journal of Clinical Oncology},
  year = {2012},
  doi = {10.1200/jco.2011.39.9824},
}

Loading related content...

Figure